Search results for "Prevention."

showing 10 items of 1632 documents

Registration of childhood cancer: Moving towards pan-European coverage?

2015

Cancer is relatively rare in childhood, but it contributes considerably to childhood mortality, years of life lost per person and late effects in survivors. Large populations need to be covered to set up meaningful studies of these rare conditions. Cancer registries ensure cancer surveillance, thus providing the basis for research as well as policy decisions. In this paper we examine coverage of childhood population by cancer registries in Europe and encourage national cancer registration. Over 200 cancer registries in various stages of development were identified as collecting data on childhood cancer patients in Europe. They cover 52% of the childhood population in the World Health Organi…

Cancer ResearchPediatricsmedicine.medical_specialtyAdolescentChildhood cancerPopulation610 Medicine & healthWorld Health OrganizationNeoplasmsEnvironmental healthHumansMedicinemedia_common.cataloged_instance1306 Cancer ResearchEuropean UnionRegistriesAge of OnsetEuropean unionChildeducationmedia_commoneducation.field_of_studyData collectionbusiness.industryIncidence (epidemiology)Infant NewbornInfantCancer10060 Epidemiology Biostatistics and Prevention Institute (EBPI)medicine.diseaseEuropeYears of potential life lostOncologyChild PreschoolData qualityPractice Guidelines as Topic2730 OncologybusinessEuropean Journal of Cancer
researchProduct

Factors associated with decision-making on prophylactic hysterectomy and attitudes towards gynecological surveillance among women with Lynch syndrome…

2020

AbstractTo prevent endometrial carcinoma in Lynch syndrome (LS), regular gynecological surveillance visits and prophylactic surgery are recommended. Previous data have shown that prophylactic hysterectomy is an effective means of cancer prevention, while the advantages and disadvantages of surveillance are somewhat unclear. We aimed to evaluate female LS carriers’ attitudes towards regular gynecological surveillance and factors influencing their decision-making on prophylactic surgery that have not been well documented. Pain experienced during endometrial biopsies was also evaluated. Postal questionnaires were sent to LS carriers undergoing regular gynecological surveillance. Questionnaires…

Cancer ResearchSURGERYmedicine.medical_treatmentPain Procedural0302 clinical medicineSurveys and QuestionnairesEpidemiologyProphylactic surgeryFinlandGenetics (clinical)Aged 80 and overRISKSurveillancemedicine.diagnostic_testObstetricsMiddle Aged16. Peace & justiceProphylactic SurgeryLynch syndrome3. Good healthDNA-Binding Proteinsprophylactic surgeryMutS Homolog 2 ProteinOncologyPatient Satisfaction030220 oncology & carcinogenesissurveillanceFemaleOriginal Article030211 gastroenterology & hepatologyMutL Protein Homolog 1AdultHeterozygotemedicine.medical_specialtyDecision Making3122 CancersHNPCCHysterectomyehkäisevä lääketiede03 medical and health sciencesSyöpätaudit - CancersGeneticsmedicineCarcinomaHumansGenetic TestingLynchin oireyhtymäAgedRetrospective StudiesHysterectomyCancer preventionbusiness.industryEndometrial cancerENDOMETRIAL CANCERmedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisEndometrial NeoplasmsLynch syndromebusinessEndometrial biopsy
researchProduct

Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations.

2013

Human papillomavirus (HPV) 58 accounts for a notable proportion of cervical cancers in East Asia and parts of Latin America, but it is uncommon elsewhere. The reason for such ethnogeographical predilection is unknown. In our study, nucleotide sequences of E6 and E7 genes of 401 HPV58 isolates collected from 15 countries/cities across four continents were examined. Phylogenetic relationship, geographical distribution and risk association of nucleotide sequence variations were analyzed. We found that the E6 genes of HPV58 variants were more conserved than E7. Thus, E6 is a more appropriate target for type-specific detection, whereas E7 is more appropriate for strain differentiation. The frequ…

Cancer ResearchSettore MED/07 - Microbiologia E Microbiologia Clinicacervical cancerSettore MED/06 - Oncologia MedicaPapillomavirus E7 ProteinsUterine Cervical NeoplasmsCervix UteriphylogenyPolymerase Chain ReactionViralPapillomaviridaePapillomaviridaePhylogenyCancerOncogene ProteinsCervical cancerGeneticsTumorGeographybiologyNucleic acid sequenceDNA NeoplasmPrognosisInfectious DiseasesOncologyHIV/AIDSFemaleHPVhuman papillomavirus type 58 E6 and E7 sequence variationsOncology and CarcinogenesisCervical intraepithelial neoplasiaRisk AssessmentArticleVaccine Relatedoncogenic riskClinical ResearchPhylogeneticsGenetic variationGeneticsBiomarkers TumormedicineHumansOncology & CarcinogenesisGenePreventionPapillomavirus InfectionsGenetic VariationInternational AgenciesDNAOncogene Proteins ViralOdds ratioUterine Cervical Dysplasiamedicine.diseasebiology.organism_classificationVirologyvariantNeoplasmSexually Transmitted InfectionsCapsid ProteinsBiomarkersFollow-Up Studies
researchProduct

Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a pr…

2013

PURPOSE To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial. PATIENTS AND METHODS Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy. The primary end point was the premature ovarian failure (POF) rate (follicle-stimulating hormone [FSH] ≥ 40 IU/L) after 1 year of follow-up. Results Eighty-four of 129 randomly assigned patients …

Cancer ResearchTime FactorsLymphomamedicine.medical_treatmentGonadotropin-Releasing Hormone -- agonistsPrimary Ovarian InsufficiencyTriptorelin Pamoate -- therapeutic uselaw.inventionGonadotropin-Releasing HormoneGynécologieRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsClinical endpointBiological Markers -- bloodNorethindrone -- therapeutic useProspective StudiesTreatment FailureProspective cohort studyTriptorelin PamoateEstradiolLymphoma Non-HodgkinLymphoma -- drug therapyMiddle AgedTriptorelinHodgkin DiseasePremature ovarian failureLuteolytic AgentsOncologyHodgkin Disease -- drug therapyDrug Therapy CombinationFemaleEstradiol -- bloodmedicine.drugAdultAntineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effectsmedicine.medical_specialtyNorethisteronemedicine.drug_classUrologyFollicle Stimulating Hormone -- bloodGonadotropin-releasing hormone agonistmedicineHumansGynecologyChemotherapybusiness.industrymedicine.diseaseLuteolytic Agents -- therapeutic useCancérologieLymphoma Non-Hodgkin -- drug therapyPremenopausePrimary Ovarian Insufficiency -- blood -- chemically induced -- prevention & controlFollicle Stimulating HormoneNorethindronebusinessBiomarkersFollow-Up Studies
researchProduct

Foreword: Implementing cancer prevention in Europe

2010

The understanding of risk factors underpinning the aetiology of many common cancers is well established, yet the conversion of this knowledge into prevention lags considerably behind. The title of this Special Issue - Implementing cancer prevention in Europe - captures the central theme within; namely, the translation of cancer epidemiology into public health policy. The Special Issue is supported by focused evidence-based case studies of how these processes might be best taken forward. (C) 2010 Published by Elsevier Ltd.

Cancer ResearchUnderpinningCancer preventionOncologySDG 3 - Good Health and Well-beingbusiness.industryEpidemiology of cancerMedicinePublic relationsbusinessPublic health policyTheme (narrative)European Journal of Cancer
researchProduct

The Porto European Cancer Research Summit 2021.

2021

Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high‐quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research acros…

Cancer Researchmedicine.medical_specialty:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]infrastructures for translational cancer researchDeclarationTranslational researchContext (language use)comprehensive cancer centresMeeting Reportclinical/prevention trials:profesiones sanitarias::medicina::medicina clínica::medicina de precisión [DISCIPLINAS Y OCUPACIONES]Translational Research Biomedicaloutcomes research:neoplasias [ENFERMEDADES]:Other subheadings::Other subheadings::/prevention & control [Other subheadings]cancer research/care/prevention continuumNeoplasmsPolitical scienceGeneticsmedicineHumansmedia_common.cataloged_instance:Health Occupations::Medicine::Clinical Medicine::Precision Medicine [DISCIPLINES AND OCCUPATIONS]Medicina personalitzadaPrecision MedicineEuropean unionRC254-282media_commongeographySummitgeography.geographical_feature_categoryHealth economics:Natural Science Disciplines::Science::Research::Biomedical Research [DISCIPLINES AND OCCUPATIONS]Neoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineCancer MissionEuropescience policy:Neoplasms [DISEASES]Medicina - InvestigacióOncologyQuality of LifeCancer researchMolecular MedicineScience policyCàncer - PrevencióOutcomes research:disciplinas de las ciencias naturales::ciencia::investigación::investigación biomédica [DISCIPLINAS Y OCUPACIONES]
researchProduct

The long road towards cancer prevention: 4 steps backward and 8 forward

2010

At the same time andpartly as a consequence, prevalence of cancer has been risingfrom about 1.5% to 3%, especially in people of higher SES.Thus, despite better diagnoses and treatments to patients,the cancer burden is still increasing. A variety of strategieswhich integrate disease prevention policies across a widerpopulation are needed to deliver better global results: oncol-ogy might be making progress in detection and treatmentbut losing ground in prevention.This narration is not new. The ‘Europe against Cancer’ pro-gramme, which ran from 1986 to about 2002,

Cancer Researchmedicine.medical_specialtyHealth PromotionOccupational safety and healthBreast cancerSDG 3 - Good Health and Well-beingRisk FactorsNeoplasmsMedicinemedia_common.cataloged_instanceHumansSocial inequalityEuropean UnionEuropean unionIntensive care medicineLife StyleHealth policymedia_commonCancer preventionbusiness.industryCancermedicine.diseaseSurgeryEuropeHealth promotionOncologybusiness
researchProduct

Lifestyle, nutrition and breast cancer: facts and presumptions for consideration

2015

Breast cancer is the most common cancer in women worldwide, and the high incidence of this cancer coupled with improvements in initial treatments has led to an ever-increasing number of breast cancer survivors. Among the prospective epidemiological studies on diet and breast cancer incidence and recurrence, to date, there is no association that is strong, reproducible and statistically significant, with the exception of alcohol intake, overweight, and weight gain. Nevertheless, many beliefs about food and breast cancer persist in the absence of supporting scientific evidence. After a comprehensive review regarding the role of lifestyle on breast cancer outcomes and a thorough study of the d…

Cancer Researchmedicine.medical_specialtyPathologylifestyleReviewOverweightlaw.inventionbody weightBreast cancerbreast cancerRandomized controlled triallawWeight managementmedicineProspective cohort studyCancer preventioncancer preventionbusiness.industryCancermedicine.diseasenutritionOncologyFamily medicineObservational studymedicine.symptombusinessecancermedicalscience
researchProduct

European code against cancer 4th edition: 12 ways to reduce your cancer risk

2015

AbstractThis overview describes the principles of the 4th edition of the European Code against Cancer and provides an introduction to the 12 recommendations to reduce cancer risk. Among the 504.6 million inhabitants of the member states of the European Union (EU28), there are annually 2.64 million new cancer cases and 1.28 million deaths from cancer. It is estimated that this cancer burden could be reduced by up to one half if scientific knowledge on causes of cancer could be translated into successful prevention. The Code is a preventive tool aimed to reduce the cancer burden by informing people how to avoid or reduce carcinogenic exposures, adopt behaviours to reduce the cancer risk, or t…

Cancer Researchmedicine.medical_specialtyQuality Assurance Health CareEpidemiologyUterine Cervical NeoplasmsCancer preventionCauses of cancerCancer screeningBreast cancerRisk FactorsEnvironmental healthCancer screeningmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unionPreventive healthcaremedia_commonCervical cancerCancer risk factorsCancer preventionbusiness.industryCancermedicine.diseaseEuropeOncology1117 Public Health And Health ServicesWorking Groups of Scientific ExpertsPractice Guidelines as TopicFemalebusiness1112 Oncology And Carcinogenesis
researchProduct

Intermittent and Periodic Fasting, Hormones, and Cancer Prevention

2021

Simple Summary Hormonal and growth factor alterations, related to an elevated food consumption and excessive adiposity, affect the regulation of genes involved in cellular processes including proliferation, differentiation and DNA repair, allowing cells to survive and proliferate despite the accumulation of mutations which lead to malignant transformation. The growth hormone/insulin growth factor-1 (GH/IGF-1)/ insulin pathway and its downstream effectors, in fact, are known to promote aging and/or age-related diseases, including cancer, in many model organisms. The restriction of nutrients is established to have strong effects on levels of hormones and growth factors, delaying the incidence…

Cancer Researchmedicine.medical_specialtyfastingDNA damagemedicine.medical_treatmentReviewInternal medicinemedicineRC254-282Cancer preventioncancer preventionbusiness.industryInsulinRegeneration (biology)agingNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerImmunosenescencemedicine.diseasegrowth hormonesEndocrinologyOncologyCancer cellDNA damagebusinessHormoneCancers
researchProduct